BioCentury
ARTICLE | Clinical News

Nektar gains on NKTR-214/Opdivo combo data

November 14, 2017 12:38 AM UTC

Nektar Therapeutics (NASDAQ:NKTR) gained $4.60 (14%) to $37.10 on Monday after reporting interim response data from the dose-escalation Phase Ib portion of the Phase Ib/II PIVOT-02 trial evaluating NKTR-214 plus Opdivo nivolumab to treat advanced or metastatic solid tumors. Nektar presented the data over the weekend at the Society for Immunotherapy of Cancer meeting in National Harbor, Md.

In 11 evaluable treatment-naïve patients with stage IV melanoma, NKTR-214 plus Opdivo led to a best overall response rate (ORR) of 64%, including two complete responses and five partial responses, plus three cases of stable disease. In 13 evaluable treatment-naïve patients with stage IV renal cell carcinoma (RCC), the combination led to a best ORR of 46%, including one complete response and five partial responses, plus five cases of stable disease. One of seven evaluable patients with stage IV RCC in the second-line setting had a partial response, with the remaining six patients all achieving stable disease. In four evaluable patients with PD-L1-negative, stage IV non-small cell lung cancer (NSCLC) in the second-line setting, the combination led to one complete response and two partial responses...